$DD earnings report

DuPont Reports Third Quarter 2026 Results Exceeds Third Quarter 2026 Guidance Raises Full Year 2026 Guidance. AlphAI read DuPont de Nemours's Third Quarter 2026 filing as strong. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readDD · Third Quarter 2026 · ended September 30, 2026

DuPont Reports Third Quarter 2026 Results Exceeds Third Quarter 2026 Guidance Raises Full Year 2026 Guidance

✓Strong quarter

Third-quarter net sales increased 4%, organic sales increased 5%, operating EBITDA increased 8%, GAAP EPS from continuing operations increased 77%, and adjusted EPS increased 62%. The Company raised full-year 2026 guidance and reported transaction-adjusted free cash flow conversion of 121%.

Revenue
$1.87B
4% y/y
Healthcare & Water Technologies
$865M
4% y/y
EPS · non-GAAP
$2.09
62% y/y
4Q'26E and Full Year 2026E outlook
4Q'26E: ~$1,825; Full Year 2026E: ~$7,190

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net sales, Three Months Ended September 30, 2026GAAP$1.87B–4%
Organic sales, Three Months Ended September 30, 2026non-GAAP5%–5%
Cost of sales, Three Months Ended September 30, 2026GAAP$1.20B––
Research and development expenses, Three Months Ended September 30, 2026GAAP$ 42––
Selling, general and administrative expenses, Three Months Ended September 30, 2026GAAP$260M––
Amortization of intangibles, Three Months Ended September 30, 2026GAAP$ 68––
Restructuring and asset related charges - net, Three Months Ended September 30, 2026GAAP$ 6––
Acquisition, integration and separation costs, Three Months Ended September 30, 2026GAAP$ 15––
Income from continuing operations before income taxes, Three Months Ended September 30, 2026GAAP$279M––
Income from continuing operations, net of tax, Three Months Ended September 30, 2026GAAP$171M–68%
Net income, Three Months Ended September 30, 2026GAAP$126M––
Net income available for DuPont common stockholders, Three Months Ended September 30, 2026GAAP$123M––
Earnings per common share from continuing operations - diluted, Three Months Ended September 30, 2026GAAP$ 1.24–77%
Earnings per common share - diluted, Three Months Ended September 30, 2026GAAP$ 0.91––
Operating EBITDA, Three Months Ended September 30, 2026non-GAAP$469M–8%
Operating EBITDA margin, Three Months Ended September 30, 2026non-GAAP25.1 %–80 bps
Adjusted earnings, Three Months Ended September 30, 2026non-GAAP$282M––
Adjusted EPS, Three Months Ended September 30, 2026non-GAAP$2.09–62%
Cash provided by operating activities - continuing operations, Three Months Ended September 30, 2026GAAP$410M–27%
Capital expenditures, Three Months Ended September 30, 2026other$71––
Adjusted free cash flow, Three Months Ended September 30, 2026non-GAAP$339M––
Transaction-adjusted free cash flow, Three Months Ended September 30, 2026non-GAAP$341M–(1%)
Transaction-adjusted free cash flow conversion, Three Months Ended September 30, 2026non-GAAP121 %––
Net sales, Nine Months Ended September 30, 2026GAAP$5.37B––
Income from continuing operations, net of tax, Nine Months Ended September 30, 2026GAAP$512M––
Net income, Nine Months Ended September 30, 2026GAAP$437M––
Earnings per common share from continuing operations - diluted, Nine Months Ended September 30, 2026GAAP$ 3.68––
Operating EBITDA, Nine Months Ended September 30, 2026non-GAAP$1.33B––
Adjusted EPS, Nine Months Ended September 30, 2026non-GAAP$ 5.61––
Cash provided by operating activities - continuing operations, Nine Months Ended September 30, 2026GAAP$1.04B––
Transaction-adjusted free cash flow, Nine Months Ended September 30, 2026non-GAAP$814M––
Transaction-adjusted free cash flow conversion, Nine Months Ended September 30, 2026non-GAAP106 %––

Segments

SegmentRevenueq/qy/y
Healthcare & Water TechnologiesHealthcare Technologies sales up mid-single digits on an organic basis led by growth in personal protection and medical packaging. Water Technologies sales up low-single digits on an organic basis on strength in industrial water, semiconductor and specialty markets, partially offset by continued disruptions in the Middle East.$865M–4%
Diversified IndustrialsBuilding Technologies sales up mid-single digits on an organic basis due to growth in North America and Asia. Industrial Technologies sales up mid-single digits on an organic basis on continued strength in aerospace and electric vehicle battery applications.$1.00B–4%

Amounts quoted below without a unit are in millions, as in the filing’s tables. Per-share figures are as printed.

4Q'26E and Full Year 2026E outlook

  • Revenue4Q'26E: ~$1,825; Full Year 2026E: ~$7,190
  • NoteOperating EBITDA (non-GAAP): 4Q'26E: ~$455; Full Year 2026E: ~$1,785
  • NoteAdjusted EPS (non-GAAP): 4Q'26E: $1.90 - $1.95; Full Year 2026E: $7.47 - $7.52
  • NoteFull Year 2026E organic growth: about 4.5%

Capital returns

  • Completed $250 million accelerated share purchase in the third quarter.
  • Substantially completed $100 million of open market share repurchases in the third quarter.
  • Announces intent to repurchase $250 million of shares in the fourth quarter.
  • Purchases of common stock and forward contracts, Nine Months Ended September 30, 2026: $ (611).
  • Dividends paid to stockholders, Nine Months Ended September 30, 2026: $ (243).

What drove it

  • Consolidated net sales were up 4% on a 5% increase in organic sales partially offset by a 1% headwind from currency.
  • Operating EBITDA increased on organic growth and productivity.
  • GAAP Income/GAAP EPS from continuing operations improved on higher segment earnings and lower interest expense and transaction costs.
  • Adjusted EPS increased on higher segment earnings and lower net interest expense, tax rate, and share count.
  • Healthcare, aerospace and industrial water end-markets showed continued strength.
  • The Reverse Stock Split became effective on June 24, 2026, and all share and share-related information in the interim Consolidated Financial Statements was retroactively adjusted.

Concerns

  • Water Technologies faced continued disruptions in the Middle East.
  • Third quarter 2025 net sales included a benefit of $15 million, or 2%, from an order timing shift from the fourth quarter 2025 due to separation-related activities, primarily in Water Technologies.
  • Third quarter 2025 net sales included a benefit of $15 million, or 2%, from an order timing shift from the fourth quarter 2025 due to separation-related activities, primarily in Industrial Technologies.
  • Loss from discontinued operations, net of tax, was $ (45) in the third quarter of 2026.
  • The filing identifies risks related to PFAS and related litigation, remediation and environmental obligations, as well as portfolio actions, trade measures, supply-chain disruption and the timing and amount of repurchases.

What to watch

  • Execution against 4Q'26E net sales of ~$1,825, operating EBITDA of ~$455, and adjusted EPS of $1.90 - $1.95.
  • Delivery of full-year organic growth of about 4.5%, operating EBITDA of about $1.785 billion, and adjusted EPS of $7.47 - $7.52 per share.
  • Completion and timing of the intended $250 million fourth-quarter share repurchase.
  • Performance in industrial water, aerospace, healthcare, construction and electric vehicle battery applications.
  • The impact of continued disruptions in the Middle East on Water Technologies.

Balance sheet and cash flow

  • Cash and cash equivalents as of September 30, 2026: $ 1,652; December 31, 2025: $ 715.
  • Long-Term Debt as of September 30, 2026: $ 3,094; December 31, 2025: $ 3,134.
  • Short-term borrowings as of September 30, 2026: $ —; December 31, 2025: $ 60.
  • Cash provided by operating activities - continuing operations, Nine Months Ended September 30, 2026: $ 1,042; Nine Months Ended September 30, 2025: $ 473.
  • Capital expenditures, Nine Months Ended September 30, 2026: $ (249); Nine Months Ended September 30, 2025: $ (246).
  • Proceeds and adjustments to proceeds from sales of businesses, net of cash divested, Nine Months Ended September 30, 2026: 1,159.
  • Cash used for financing activities - continuing operations, Nine Months Ended September 30, 2026: $ (842); Nine Months Ended September 30, 2025: $ (538).

Analysis

DuPont reported third-quarter net sales of $1,868 million, up 4% from $1,795 million, with 5% organic sales growth partly offset by a 1% currency headwind. Both segments contributed: Healthcare & Water Technologies recorded $865 million of sales, up 4%, while Diversified Industrials recorded $1,003 million, also up 4%. Management cited continued strength in healthcare, aerospace and industrial water, alongside growth in personal protection, medical packaging, construction, and electric vehicle battery applications.

Profitability improved across the reported operating measures. Operating EBITDA increased 8% to $469 million and operating EBITDA margin expanded 80 basis points to 25.1%. Healthcare & Water Technologies operating EBITDA rose to $263 million from $246 million, with margin increasing to 30.4% from 29.6%. Diversified Industrials operating EBITDA rose to $242 million from $219 million, and margin increased to 24.1% from 22.7%. DuPont attributed the consolidated EBITDA improvement to organic growth and productivity.

GAAP income from continuing operations was $171 million, up 68% from $102 million, while diluted GAAP EPS from continuing operations was $1.24, up 77% from $0.70. Adjusted EPS rose 62% to $2.09 from $1.29. The Company attributed adjusted EPS growth to higher segment earnings and lower net interest expense, tax rate, and share count. Results remain presented on a continuing-operations basis following the separation of the Electronics Business and the Aramids Divestiture, while the quarter included a $ (45) loss from discontinued operations, net of tax.

Cash generation was a central feature of the quarter. Cash provided by operating activities from continuing operations was $410 million, capital expenditures were $71 million, and transaction-adjusted free cash flow was $341 million. Transaction-adjusted free cash flow conversion was 121%, compared with 192% in the prior-year quarter. For the first nine months, cash provided by operating activities from continuing operations was $1,042 million and transaction-adjusted free cash flow was $814 million. Cash and cash equivalents were $1,652 million at September 30, 2026, while long-term debt was $3,094 million.

Capital allocation included completion of a $250 million accelerated share purchase and substantial completion of $100 million of open-market repurchases during the third quarter, plus an announced intent to repurchase $250 million of shares in the fourth quarter. DuPont raised its full-year outlook to net sales of ~$7,190, operating EBITDA of ~$1,785, adjusted EPS of $7.47 - $7.52, and organic growth of about 4.5%. The fourth-quarter outlook calls for net sales of ~$1,825, operating EBITDA of ~$455, and adjusted EPS of $1.90 - $1.95.

Management, verbatim

We delivered another quarter of consistent, high-quality performance, once again exceeding our financial guidance.

Lori Koch, DuPont Chief Executive Officer

Mid-single-digit organic growth, strong operating leverage and disciplined capital allocation drove significant adjusted EPS growth. Additionally, we delivered strong free cash flow performance, with 121% conversion, underscoring the quality of our earnings and effective execution.

Lori Koch, DuPont Chief Executive Officer

Our results once again exceeded our financial expectations, demonstrating the strength of our operating model and consistent execution across the businesses. We are again raising our full-year financial outlook and now expect organic growth to be about 4.5%, operating EBITDA to be about $1.785 billion and adjusted EPS to be in the range of $7.47 - $7.52 per share, all at or above the high end of our previously communicated guidance.

Antonella Franzen, DuPont Chief Financial Officer

Not in the filing

stated, not guessed
  • Gross margin was not reported.
  • GAAP operating income was not reported as a line item.
  • A quarterly dividend declaration or per-share dividend amount was not reported.
  • A prior-quarter comparison was not reported for the reported quarterly metrics.
  • Prior financial outlook figures were not provided, so actual results cannot be compared with prior guidance.
  • Forward gross margin, operating expenses, and tax-rate guidance were not reported.
  • Quarterly cash, debt, and net-debt comparisons with the prior-year quarter were not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readDD · Second Quarter 2026 · ended June 30, 2026

DuPont Reports Second Quarter 2026 Results Exceeds Second Quarter 2026 Guidance Raises Full Year 2026 Guidance

✓Strong quarter

Net sales and organic sales each increased 4%, operating EBITDA increased 6%, adjusted EPS increased 48%, and transaction-adjusted free cash flow increased 205%. The company also raised full-year 2026 guidance.

Revenue
$1.82B
4% y/y
Healthcare & Water Technologies
$856M
5% y/y
EPS · non-GAAP
$1.88
48% y/y
2H'26E and Full Year 2026E outlook
2H'26E: $3,660 - $3,690; Full Year 2026E: $7,160 - $7,190

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net salesGAAP$1.82B–4%
Organic salesnon-GAAP4%–4%
GAAP Income from continuing operationsGAAP$191M–n.m.
Operating EBITDAnon-GAAP$448M–6%
Operating EBITDA marginnon-GAAP24.6%–40 bps
GAAP EPS from continuing operationsGAAP$1.37–n.m.
Adjusted EPSnon-GAAP$1.88–48%
Cash provided by operating activities from continuing operationsGAAP$400M–n.m.
Capital expendituresother$76M––
Separation-related transaction costs and other paymentsother$2M––
Transaction-adjusted free cash flownon-GAAP$326M–205%
Transaction-adjusted free cash flow conversionnon-GAAP127%––
Healthcare & Water Technologies Operating EBITDAnon-GAAP$258M–4%
Healthcare & Water Technologies Operating EBITDA marginnon-GAAP30.1%–(30) bps
Diversified Industrials Operating EBITDAnon-GAAP$213M–7%
Diversified Industrials Operating EBITDA marginnon-GAAP22.1%–70 bps

Segments

SegmentRevenueq/qy/y
Healthcare & Water TechnologiesNet sales increased on organic sales growth of 4% and a currency benefit of 1%. Healthcare Technologies sales were up mid-single digits on an organic basis on broad-based growth led by personal protection and biopharma. Water Technologies sales were up low-single digits on an organic basis on continued strength in industrial water and semiconductor markets, partially offset by weakness in the Middle East.$856M–5%
Diversified IndustrialsNet sales increased on organic sales growth in the quarter. Building Technologies sales were up low-single digits on an organic basis due to growth in residential and non-residential construction markets. Industrial Technologies sales were up mid-single digits on an organic basis on continued strength in aerospace coupled with growth in electric vehicle applications.$963M–3%

Amounts quoted below without a unit are in millions, as in the filing’s tables. Per-share figures are as printed.

2H'26E and Full Year 2026E outlook

  • Revenue2H'26E: $3,660 - $3,690; Full Year 2026E: $7,160 - $7,190
  • NoteOperating EBITDA: 2H'26E: $890 - $910; Full Year 2026E: $1,750 - $1,770
  • NoteAdjusted EPS: 2H'26E: $3.65 - $3.80; Full Year 2026E: $7.17 - $7.32
  • NoteFull-year 2026 operating EBITDA guidance midpoint: approximately $1.76 billion
  • NoteAdjusted EPS guidance midpoint: $7.24 per share
  • NoteExpectation for organic sales growth: slightly above 4%
  • NoteSecond-half organic sales growth expectation: mid-single digit organic sales growth

Capital returns

  • Announces intent to repurchase $250 million of shares in the third quarter.

What drove it

  • Consolidated operating EBITDA increased on organic growth and productivity.
  • GAAP Income and GAAP EPS from continuing operations improved on higher segment earnings and lower interest expense and transaction costs.
  • Adjusted EPS increased on higher segment earnings, lower net interest expense and a lower tax rate.
  • Healthcare & Water Technologies operating EBITDA increased on organic growth and productivity, partially offset by growth investments.
  • Diversified Industrials operating EBITDA and margin increased on organic growth, favorable mix and productivity.
  • The company cited continued strength across healthcare, industrial water, and aerospace end-markets.

Concerns

  • Healthcare & Water Technologies operating EBITDA margin decreased 30 basis points as organic growth and productivity were more than offset by less favorable mix and growth investments.
  • Water Technologies strength in industrial water and semiconductor markets was partially offset by weakness in the Middle East.
  • The filing identifies risks and costs related to the arrangement to share future eligible PFAS costs among DuPont, Corteva, Inc. and The Chemours Company.
  • The financial results of the divested Aramids Business and the Electronics Business are reflected as discontinued operations.

What to watch

  • Delivery of 2H'26E net sales of $3,660 - $3,690, operating EBITDA of $890 - $910 and adjusted EPS of $3.65 - $3.80.
  • Whether organic sales growth reaches the expectation of slightly above 4% for full-year 2026 and mid-single digit growth in the second half.
  • Margin progression in Healthcare & Water Technologies following the 30 basis point decline.
  • Continued strength in healthcare, industrial water, aerospace, construction and electric vehicle applications.
  • Execution of the intent to repurchase $250 million of shares in the third quarter.

Balance sheet and cash flow

  • Cash provided by operating activities from continuing operations was $400 million.
  • Capital expenditures were $76 million.
  • Separation-related transaction costs and other payments were $2 million.
  • Transaction-adjusted free cash flow was $326 million, representing 127% conversion.
  • The Aramids Divestiture was completed on April 1, 2026 for pre-tax cash proceeds of approximately $1.2 billion, subject to customary transaction adjustments, a note receivable in the principal amount of $300 million and a non-controlling common equity interest valued at $325 million.

Analysis

DuPont reported a strong second quarter ended June 30, 2026. Net sales were $1,819 million, up 4%, with organic sales also up 4%. Operating EBITDA increased 6% to $448 million and operating EBITDA margin increased 40 bps to 24.6%. GAAP Income from continuing operations was $191 million, compared with $24 million, while GAAP EPS from continuing operations was $1.37, compared with $0.17.

Growth was present in both reporting segments. Healthcare & Water Technologies generated net sales of $856 million, up 5%, including 4% organic growth and a 1% currency benefit. Healthcare Technologies benefited from personal protection and biopharma, while Water Technologies saw continued strength in industrial water and semiconductor markets. Diversified Industrials generated net sales of $963 million, up 3%, supported by construction-market growth, continued aerospace strength and growth in electric vehicle applications.

Profitability was led by productivity and mix in Diversified Industrials, where operating EBITDA increased 7% to $213 million and margin increased 70 bps to 22.1%. Healthcare & Water Technologies operating EBITDA increased 4% to $258 million, but margin declined 30 basis points to 30.1% because less favorable mix and growth investments more than offset organic growth and productivity. At the consolidated level, adjusted EPS increased 48% to $1.88, with higher segment earnings, lower net interest expense and a lower tax rate cited as drivers.

Cash generation strengthened materially. Cash provided by operating activities from continuing operations was $400 million, capital expenditures were $76 million and separation-related transaction costs and other payments were $2 million. These items resulted in transaction-adjusted free cash flow of $326 million and 127% conversion. The company announced its intent to repurchase $250 million of shares in the third quarter.

Management raised full-year 2026 guidance to net sales of $7,160 - $7,190, operating EBITDA of $1,750 - $1,770 and adjusted EPS of $7.17 - $7.32. The stated full-year midpoint targets are approximately $1.76 billion of operating EBITDA and $7.24 per share of adjusted EPS, with organic sales growth expected to be slightly above 4%. The second-half outlook calls for net sales of $3,660 - $3,690, operating EBITDA of $890 - $910, adjusted EPS of $3.65 - $3.80 and mid-single digit organic sales growth.

Management, verbatim

We delivered another strong quarter, exceeding our financial guidance and demonstrating our focus on consistent execution

Lori Koch, DuPont Chief Executive Officer

Mid-single digit organic growth, strong margin expansion, coupled with robust adjusted EPS growth and free cash flow generation underscore the strength of our market-leading businesses and reflect disciplined execution of our strategic priorities, supported by our ongoing focus on excellence and productivity.

Lori Koch, DuPont Chief Executive Officer

Our strong execution and market-driven growth continue to translate into higher earnings and free cash flow generation. As a result of our second quarter outperformance, we are again raising the midpoint of our full-year 2026 operating EBITDA guidance to approximately $1.76 billion and adjusted EPS guidance to $7.24 per share, while increasing our expectation for organic sales growth to slightly above 4%.

Antonella Franzen, DuPont Chief Financial Officer

Not in the filing

stated, not guessed
  • Prior-quarter values and quarter-over-quarter comparisons for reported metrics.
  • Gross profit and gross margin.
  • GAAP operating income and GAAP operating margin.
  • Total net income, net income attributable to common stockholders and diluted share count.
  • Cash balance, debt balance and other period-end balance-sheet metrics.
  • Dividend declaration or payment details.
  • Completed share repurchases during the reported quarter.
  • Full-year 2026 guidance for gross margin, operating expenses, tax rate, operating cash flow, free cash flow and capital expenditures.
  • Prior outlook figures, which were not provided, for comparison with reported results.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about DD earnings dates

When is DuPont de Nemours's next earnings date?
AlphAI has no date for DD yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.